Genscript Biotech (1548) Aperçu de l'action
Genscript Biotech Corporation, une société holding d'investissement, fabrique et vend des produits et des services de recherche en sciences de la vie aux États-Unis d'Amérique, en Europe, en Chine continentale, en Europe, dans la région Asie-Pacifique et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 6/6 |
| Croissance future | 3/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour 1548 à partir de nos contrôles de risques.
1548 Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeGenscript Biotech Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | HK$13.31 |
| Plus haut sur 52 semaines | HK$19.40 |
| Plus bas sur 52 semaines | HK$9.95 |
| Bêta | 0.91 |
| Variation sur 1 mois | 7.69% |
| Variation sur 3 mois | 6.91% |
| Variation sur 1 an | 19.05% |
| Variation sur 3 ans | -36.92% |
| Variation sur 5 ans | -30.24% |
| Évolution depuis l'introduction en bourse | 908.33% |
Nouvelles et mises à jour récentes
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).Recent updates
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).1548: Higher Future P/E Assumptions Will Support Ongoing Upside Potential
Analysts have adjusted their HK$ price target for Genscript Biotech to reflect updated views on discount rate, long term profit margins and a higher assumed future P/E multiple. This has resulted in a modest recalibration of fair value rather than a wholesale shift in the investment case.1548: Slightly Lower Future P/E Will Still Support Attractive Upside Potential
Analysts have trimmed their price target on Genscript Biotech to reflect a slightly lower assumed future P/E multiple, while keeping fair value broadly unchanged at about HK$22.12. They cite fine tuning of discount rate and margin assumptions rather than any major shift in the core outlook.1548: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have trimmed their fair value estimate for Genscript Biotech from $23.52 to $22.12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Genscript Biotech held an Analyst/Investor Day, giving the market a closer look at its business, capital plans, and the assumptions that feed into analyst models (Key Developments).Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
Nov 03
Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Oct 10We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
Sep 18Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
Sep 08Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Despite a sharp decline in consensus revenue growth forecasts and a substantial jump in future P/E, analysts have raised Genscript Biotech's fair value estimate from HK$21.61 to HK$23.01. What's in the News GenScript Biotech launched a new global brand platform, "Scripting Possibilities," alongside a refreshed visual identity and expanded marketing initiatives to drive growth and strengthen global brand presence.Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues
Jul 29At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?
Jul 24Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
May 14Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Apr 07Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump
Feb 12Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 20Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Aug 02Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
May 10Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 13Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Mar 13Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 26Is Genscript Biotech (HKG:1548) A Risky Investment?
Nov 21Is Genscript Biotech (HKG:1548) A Risky Investment?
Aug 22Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
Apr 04Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
Apr 03Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 02Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate
Feb 07Rendement pour les actionnaires
| 1548 | HK Life Sciences | HK Marché | |
|---|---|---|---|
| 7D | -2.2% | 3.0% | 0.09% |
| 1Y | 19.1% | 46.0% | 20.8% |
Rendement vs Industrie: 1548 a sous-performé le secteur Hong Kong Life Sciences qui a rapporté 46 % au cours de l'année écoulée.
Rendement vs marché: 1548 a sous-performé le marché Hong Kong qui a rapporté 20.8 % au cours de l'année écoulée.
Volatilité des prix
| 1548 volatility | |
|---|---|
| 1548 Average Weekly Movement | 6.2% |
| Life Sciences Industry Average Movement | 7.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.5% |
Cours de l'action stable: 1548 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Hong Kong.
Volatilité au fil du temps: La volatilité hebdomadaire de 1548 ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2002 | 6,165 | Sherry Shao | www.genscript.com |
Genscript Biotech Corporation, une société holding d'investissement, fabrique et vend des produits et services de recherche en sciences de la vie aux États-Unis d'Amérique, en Europe, en Chine continentale, en Europe, dans la région Asie-Pacifique et dans le monde entier. Ses activités s'articulent autour de trois segments : Services et produits des sciences de la vie ; Services de développement de produits biologiques ; et Produits de biologie synthétique industrielle. Le segment des services et produits des sciences de la vie fournit des produits et des services dans diverses catégories, notamment la synthèse de gènes, la synthèse d'oligonucléotides, la synthèse de peptides, l'ingénierie des protéines, le développement d'anticorps et les équipements et consommables des sciences de la vie, tels que les outils de diagnostic moléculaire et le matériel d'édition du génome pour les études biologiques, la découverte de produits pharmaceutiques et de médicaments, le diagnostic de maladies et les vaccins, l'agriculture, les études environnementales et l'industrie agroalimentaire.
Genscript Biotech Corporation Résumé des fondamentaux
| 1548 statistiques fondamentales | |
|---|---|
| Capitalisation boursière | HK$29.12b |
| Bénéfices(TTM) | -HK$4.17b |
| Recettes(TTM) | HK$7.52b |
Le site 1548 est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| 1548 compte de résultat (TTM) | |
|---|---|
| Recettes | US$959.53m |
| Coût des recettes | US$406.32m |
| Marge brute | US$553.20m |
| Autres dépenses | US$1.09b |
| Les revenus | -US$532.83m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.24 |
| Marge brute | 57.65% |
| Marge bénéficiaire nette | -55.53% |
| Ratio dettes/capitaux propres | 7.1% |
Quelles ont été les performances à long terme de 1548?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/04 07:35 |
| Cours de l'action en fin de journée | 2026/05/04 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Genscript Biotech Corporation est couverte par 13 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wai Chak Yuen | Daiwa Securities Co. Ltd. |